Stopping MS In Its Tracks - National Multiple Sclerosis Society

Skip to navigation Skip to content

Stopping MS In Its Tracks

Share

There are more potential MS therapies in development today than at any other time in history, and a variety of therapies exist, largely for those with relapsing forms of multiple sclerosis. For some, these treatments reduce the number and severity of attacks and slow disease activity.
 
We are making significant progress in stopping MS:
  • The Society joined with NIH to launch a therapy trial of the re-purposed therapy ibudilast in primary-progressive and secondary-progressive MS.
  • The global Progressive MS Alliance held its first scientific meeting to identify challenges and opportunities, and released its first request for research applications to address gaps in knowledge and research tools.
  • There is increasing understanding that malfunctioning mitochondria, the tiny energy producers of cells (like battery packs), may contribute to nervous system damage in MS, opening up possibilities for preventing that damage. This and other reports related to understanding MS damage and its potential repair were reported at the ECTRIMS conference.
  • An international team has reported the feasibility and safety of using a patient’s own altered blood cells to reduce immune responses against specific components of myelin.
  • A report was published from the International Pediatric MS Study Group's Therapeutic Summit Workshop, outlining optimal trial designs for studying disease-modifying therapies in children with MS to improve care.
  • A large meeting of the National MS Society-launched MS Outcome Assessments Consortium and the U.S. Food and Drug Administration cleared a pathway for a new tool for improving and speeding clinical trials in MS.
  • The Society contributed to two efforts to speed development of neuroprotective therapies - Collaborative CNS Screening Initiative, along (with the Alzheimer’s Drug Discovery Foundation and Beyond Batten Disease Foundation), and the MS-SMART Trial (with the MS Society of the UK), which is testing three neuroprotective agents.
But more must be done to stop disease progression for everyone affected by MS – including those with progressive forms. We must stop the disease in its tracks and prevent further loss for people by speeding the development of new disease-modifying drugs and symptomatic treatments, including alternative and complementary therapies. We need to:
  • Better understand the role the immune system plays in the cause of MS and in ongoing disease activity
  • Support academic and commercial research leading toward clinical trials of new therapies to stop damage and progression of disability
  • Ensure that we understand health care issues and gather data to advocate for policies that enable everyone with MS to access quality care and treatment
  • Understand the mechanisms that cause tissue injury and that drive disease progression.
Read more about our successes and goals for stopping MS.

Research news about stopping MS in its tracks

More News

Share